Equibles does not estimate personal net worth.
Get an email with a short summary when Orthofix Medical Inc. publishes a filing, an earnings call transcript or a press release.
Get OFIX alertsJulie Andrews is recorded as CFO at Orthofix Medical Inc. (OFIX). The newest filing on record that lists Julie Andrews as CFO at Orthofix Medical Inc. (OFIX) is dated April 30, 2025. Orthofix Medical Inc. reported in an 8-K filed January 17, 2024 that Julie Andrews was appointed Chief Financial Officer, effective January 16, 2024. Orthofix Medical Inc. reported in an 8-K filed January 17, 2024 that Julie Andrews was appointed Chief Financial Officer, effective January 15, 2024. Orthofix Medical Inc. reported in an 8-K filed January 9, 2024 that Julie Andrews was appointed Chief Financial Officer, effective January 15, 2024. Julie Andrews has spoken on 11 earnings calls and 4 other investor events across 1 company, most recently for Orthofix Medical Inc. on August 12, 2026. Orthofix Medical Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Orthofix Medical Inc. includes Catherine M. Burzik (CEO and Chairman), Jon Serbousek (CEO and Chairman), Massimo Calafiore (CEO and Board Member) and 7 others.
“Julie Andrews has officially stepped into the role of Chief Financial Officer (CFO).”
“On January 15, 2024, Julie Andrews began service as Chief Financial Officer of Orthofix Medical Inc. (the “Company”).”
“And all of this drive the decision that we just made. and i'll answer your question regarding guidance so our updated guidance reflects several moving pieces on the positive side is the reimbursement restoration as well as a european mdr related inventory purchase in the back half of the year and strengthening that…”
“For purposes of consistency, the growth rates I'll reference today are on a pro forma, constant currency basis and exclude the impact from discontinued M6 product lines.”
“Yeah, so when you normalize in Q1 for the selling day and then also the CMS team's impact where there was a pilot program, our growth was approximately 5% in the quarter, which was in line with our expectations.”
“All growth rates I'll reference today are pro forma constant currency, excluding the impact from discontinued M6 product lines. We delivered a disciplined start to 2026 reflecting an execution that is consistent with our plan.”
“And then you look at all the operational improvements that have gone on just to make the company structurally better. I think those are at the beginning of being reflected and not yet fully in the in the valuation.”
Start not stated–present
Last confirmed April 30, 2025
Medical Devices · Healthcare
CFO
